Eli Lilly has licensed exclusive worldwide rights to Ignyta’s Phase I taladegib oncology development program, in a deal the San Diego biotech said could generate up to $53 million-plus. Taladegib is an oral bioavailable small molecule hedgehog/smoothened antagonist. The compound has achieved clinical proof-of-concept and a recommended Phase II dose based on earlier clinical studies. Continue reading
Tag Archives: Erivedge

Targeted therapies for cancer – overview
The National Cancer Institute has a very informative, yet easy to understand overview presented as a Q&A – Targeted Cancer Therapies. Continue reading